Algernon Pharmaceuticals Receives Japanese Patent Notice of

VANCOUVER, British Columbia,Nov 08, 2023 (WORLD WIRE SERVICE)–Algernon Pharmaceuticals Inc ( the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a professional phase pharmaceutical advancement firm delights in to introduce that it has actually obtained a Notice of Allowance from the Japanese Patent Office for patent applicationNo 2021-512244 qualified “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast).

The innovation declares dealing with nonalcoholic fatty liver condition (NAFLD), consisting of nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular cancer, withRepirinast The base insurance claims of the patent will certainly stand with 2038, omitting any type of patent term modifications or expansions which might supply extra defense. The Company was lately provided a patent from the United States patent workplace for Repirinast in NASH …